(NASDAQ: ZVRA) Zevra Therapeutics's forecast annual revenue growth rate of 51.5% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.76%.
Zevra Therapeutics's revenue in 2023 is $10,458,000.On average, 2 Wall Street analysts forecast ZVRA's revenue for 2023 to be $835,912,559, with the lowest ZVRA revenue forecast at $550,643,280, and the highest ZVRA revenue forecast at $1,121,181,838. On average, 1 Wall Street analysts forecast ZVRA's revenue for 2024 to be $1,342,240,488, with the lowest ZVRA revenue forecast at $1,342,240,488, and the highest ZVRA revenue forecast at $1,342,240,488.
In 2025, ZVRA is forecast to generate $1,124,290,476 in revenue, with the lowest revenue forecast at $1,124,290,476 and the highest revenue forecast at $1,124,290,476.